Pro Pointer, Inc. (PINKSHEETS: PPII), through its wholly owned subsidiary Coenzyme-A Technologies, Inc., today announced that their product Coenzyme-A, according to famous nutritional authors Phyllis A. Balch, CNC and James F. Balch, MD in the Fourth Edition of the best selling nutritional guide to natural health "Prescription for Nutritional Healing," reduces free radical damage to LDL cholesterol and decreases human platelet aggregation by supporting the immune system's detoxification of many dangerous substances. It provides an all-natural way to maintain the healthy, normal functioning of the heart and the whole cardiovascular system.

Heart disease is the leading cause of death in the United States. Clogged arteries (atherosclerosis) can set the stage for life threatening heart attacks. Published research shows that a deficiency of metabolic enzymes exists globally, specifically the "Master Coenzyme, Coenzyme-A." Coenzyme-A Technologies, Inc. has applied new technology to the formulation of the world's first and only development of Coenzyme-A and Acetyl Coenzyme-A nutraceutical supplements.

ABOUT COENZYME-A TECHNOLOGIES, INC. -- Coenzyme-A Technologies, Inc. is an innovative company that has applied new technology to the formulation and manufacture of a series of proprietary products which address nutritional deficiencies that result from the stress of modern day living, chemical imbalances within the body, and the effects of aging. Coenzyme-A is the first nutraceutical product to combine nutritional components that can be successfully used by the body to support its manufacture and utilization of cellular Coenzyme-A (The Master Coenzyme). Coenzyme-A contains a specific set of substrates that are designed to assist the body in converting fats, carbohydrates and proteins into energy at the cellular level. See Company website -- www.coenzyme-a.com.

FORWARD LOOKING STATEMENTS

The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Such forward-looking statements involve known and unknown risks and uncertainties, including all business uncertainties relating to product development, marketing, market acceptance, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.